News

Get the latest on BIO's announcements, positions and views on everything from healthcare to biofuels. 

Press Releases
BIO Reiterates Lack of Basis for Mexico’s Ban on…
Seed technology companies comply with Mexico’s biosafety regulations, and Mexico should do the same, BIO said today in its response to the panel set up to determine if Mexico’s ban on imports of genetically modified corn violate its commitments…
Biotechnology is a national security Imperative,…
BIO President & CEO John F. Crowley announced today that BIO would take several important steps to reaffirm the organization’s position with regards to national security and the role that the industry plays as a vital strategic asset: “As a…
WTO 13th Ministerial Conference outcome "positive…
Following the conclusion of the WTO 13th Ministerial Conference in Abu Dhabi, John Murphy -- BIO's Chief Policy Officer -- made the following statement: “We are encouraged that WTO Members did not agree to extend an intellectual property…
Letters, Testimony, & Comments
BIO Comments to HHS Centers for Medicare &…
We are writing on behalf of the Biotechnology Innovation Organization (BIO) to provide comments on the Centers for Medicare & Medicaid Services’ Draft CY 2025 Part D Redesign Program Instructions.
BIO Comments to HHS on Advance Notice of…
CMS proposes updates to the RxHCC to reflect the impact of the new 2025 Part D benefit structure per the Inflation Reduction Act (IRA).
BIO Request for Information to U.S. House…
The Biotechnology Innovation Organization (BIO) appreciates the opportunity to comment on the U.S. Committee on Education and the Workforce’s (Committee’s) Request for Information on Reforms to Increase Affordability and Quality in Employer…
Amicus Briefs
BIO FILES AMICUS BRIEF CHALLENGING FTC’S…
The Biotechnology Innovation Organization (BIO) today signed onto an amicus brief to challenge the Federal Trade Commission (FTC) lawsuit to block the acquisition of Horizon by Amgen. The amicus brief was filed in the U.S. District Court, Northern…
BIO Files Amicus Brief in U.S. ex rel. Scutte v…
BIO has filed an amicus brief in U.S. ex rel. Scutte v. SuperValu Inc., which addresses the issue of the intent requirement under the False Claims Act (FCA). Specifically, BIO urges the Court to uphold the view that a firm does not…
BIO JOINS AMICUS BRIEF CHALLENGING COURT’S…
The Biotechnology Innovation Organization (BIO) today signed onto an amicus brief to challenge a District Court’s unprecedented ruling (related to a single drug known as mifepristone) that would create regulatory barriers and potentially upend FDA’s…